Cynapsus Therapeutics (NASDAQ: CYNA) is one of 296 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Cynapsus Therapeutics to related companies based on the strength of its earnings, risk, valuation, analyst recommendations, institutional ownership, profitability and dividends.
This is a breakdown of current ratings and price targets for Cynapsus Therapeutics and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cynapsus Therapeutics Competitors||766||3051||11239||227||2.71|
As a group, “Bio Therapeutic Drugs” companies have a potential upside of 35.79%. Given Cynapsus Therapeutics’ rivals higher probable upside, analysts plainly believe Cynapsus Therapeutics has less favorable growth aspects than its rivals.
Risk and Volatility
Cynapsus Therapeutics has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, Cynapsus Therapeutics’ rivals have a beta of 6.66, meaning that their average share price is 566% more volatile than the S&P 500.
This table compares Cynapsus Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cynapsus Therapeutics Competitors||-5,492.74%||-451.92%||-42.73%|
Valuation & Earnings
This table compares Cynapsus Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Cynapsus Therapeutics Competitors||$263.26 million||$68.25 million||-6.44|
Cynapsus Therapeutics’ rivals have higher revenue and earnings than Cynapsus Therapeutics. Cynapsus Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
56.6% of Cynapsus Therapeutics shares are held by institutional investors. Comparatively, 50.4% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 16.4% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Cynapsus Therapeutics Company Profile
Cynapsus Therapeutics Inc is a Canada-based specialty central nervous system (CNS) pharmaceutical company. It develops a sublingual thin film for the potential treatment for on-demand management of debilitating OFF episodes associated with Parkinson’s disease (PD). The Company completed a Phase two clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine. Apomorphine is the only molecule approved for acute, intermittent treatment of OFF episodes for advanced PD patients, but is currently only approved as a subcutaneous injection in the United States. APL-130277 is a turning ON medication designed to convert a PD patient from the OFF to the ON state while avoiding the issues associated with subcutaneous delivery of apomorphine. It is designed to convert all types of OFF episodes, including morning OFF episodes. Furthermore, the Company has initiated its pivotal Phase three clinical program for APL-130277.
What are top analysts saying about Cynapsus Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cynapsus Therapeutics Inc and related companies.